Anti-PD-1 Monotherapy

Mechanism

Related News

AI Transforms Oncology Trials; Aethlon Advances Hemopurifier Cancer Study in Australia

Mar 18, 2026

Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.

Early ctDNA Changes Predict Survival in Advanced Melanoma Treated With Immunotherapy

Mar 13, 2026

Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.